The report of the International Expert Advisory Committee to the Nutrition Foundation on the Relevance of Mouse Liver Hepatoma to Human Carcinogenic Risk is addressed elsewhere as a scientific document in the Letters to the Editor of this issue. Because of the overriding concern of many in the scientific community and in the regulatory arena about the meaning of the mouse liver lesions in terms of estimating human risk, the editors considered it appropriate to present opinions and facts regarding this controversial subject.
First, to put the matter into perspective, the subject of rodent liver lesions might better have been addressed as a whole rather than discussing the mouse separately. Most investigators are more comfortable with, and confident of the response of the rat liver to chemicals than with the response of the mouse liver and accept rat data as more relevant to detection of potential human hazards. The two species, rat and mouse, clearly differ in sensitivity to chemicals as evaluated by the gradation of liver lesions ranging from focal change to hepatocellular carcinoma. Consideration of the two species together would have provided comparative data on which to base rational discussion of the usefulness (or lack thereof) of mouse liver responses.
The Committee should be congratulated and commended on the choice of the term hepatoma, to address to the mouse liver tumor. Whether by design or as by subconscious admission that less is known about the mouse liver nodule than some would imply in their writings, the term is significant in the context of the report. In previous years investigators used this term to denote a nodule, usually without further connotation. These were the honest years before regulatory and other prcssures forced diagnoses based as much on imagination as on knowledge and understanding of the neoplasm biology. Perhaps a return to the use of the term hepatoma, when in doubt, would be preferable to calling all proliferative lesions in the mouse liver cancer or pre-cancerous lesions, as some do and as regulators treat them.
Mouse liver neoplasms generally do not invade surrounding tissues; they rarely metastasize, and they seldom, in the absence of other disease, shorten the life of the mouse. In short, the mouse liver tumor fails to exhibit the biological behavior characteristic of hepatocellular carcinoma in other species, including the rat. Moreover, proliferative lesions in the mouse liver which most reasonable pathologists would agree are benign on histologic grounds, will grow when transplanted into adequate hosts.
Despite the progress that has been made in recent years with respect to mechanisms of carcinogenesis, we are a ways away from understanding precisely how cells are initiated by hepatocarcinogens and how some are pushed toward malignancy while others go nowhere. Most hepatocarcinogens require biological activation to reactive species which can then bind to macromolecules, particularly DNA. But does the formation of DNA adducts ensure that liver cancer will follow? Certainly not! Many hepatocarcinogens bind to DNA of nontarget organs i.e. MBN binds to liver DNA but does not cause cancer at that site. However, binding and the formation of adducts does raise the level of concern about a given chemical.
It is as logical to propose that aberrant or hypomethylation of liver cell DNA is as closely associated with hepatocarcinogenesis as is adduct formation. Indeed, more than thirty years ago the laboratory of W.S. Salmon reported that diets low in methyl groups resulted in liver cell cancer in rats. Now, thirty years later, some of us may be involved in "re-discovering the wheel" by confirming Salmon's work. Just as the recognition that hepatitis B-virus integrates with DNA of liver cells in the cancer patient promises to lead to an understanding and perhaps prevention of human hepatocarcinoma, so should the aberrant or hypomethylated liver DNA in choline deficient rats and mice lead us to a better understanding of hepatocarcinoma in these species. Only when we will be better prepared to deal with issues laid out by the International Expert Committee in regard to the relevance of mouse hepatoma to human carcinogenic risk.
The Committee points out that the criteria for diagnosing mouse liver tumors are available and imply that these are generally accepted; but are they? There seems to be less than complete consensus about diagnostic criteria for focal proliferative lesions, hyperplastic nodules, adenomas and 113 carcinomas in mouse liver. In fact, quite often, when groups of pathologists are convened to consider diagnoses of mouse and rat liver tumors, the questions are resolved by vote. This is clearly not the best way to handle such matters, particularly with more than 20 years of testing behind us and literally tens of thousands of liver tumors examined by many and experienced pathologists. Faced with disagreements on diagnosis and pressures to make decisions and to get reports out, pathologists and other consultants to large programs may have been unduly influenced by the opinions based consciously or subliminally on matters of expediency. Regulatory decisions have, in fact, been made on the basis of controversial diagnoses and less than adequate bioassay data.
In the context of this discussion, and putting aside the question of validity of diagnoses, the data and arguments put forth by von Wittenau et a1 (recently in an issue of Fundamental and Applied Toxicology), are worthy of serious consideration. They present a review suggesting strongly that the mouse bioassay in fact appears to be redundant. The funds and other resources expended on mouse bioassays might better be used in expanding the database along other lines of investigations which contribute to understanding carcinogenesis. Toxicokinetics, binding and adduct formation, DNA repair, metabolic studies in general, exhaustive chronic rat studies would in toto, likely provide information worthy of a much higher level of confidence than arguments about equivocal mouse liver lesions.
The broad sweeping statements made in the report in the last paragraph of conclusions on page 5 are not supported by the data reviewed in the remainder of the report and they do not exactly concur with the reasonable statements for con-cern raised on pages 31 and 32. "Nodular hyperplasias" have not been unequivocally equated to cancer, even though they are often present in the same liver in which a true hepatocellular carcinoma resides. If this were the case, short-term exposures, could substitute for many 2 year studies.
In addition, I am not personally aware of many human pathologists who would agree that the criteria used for classification of benign hepatic tumors in humans are without controversy or who regard adenomas of the liver, as definitive premalignant lesions. How, then, can we claim more significance for the mouse lesions?
In short, the conclusions in the last paragraph on page 4 of the report appear to have been formed without adequate time and thought devoted to the consequences that such statements elicit. Regarding the statements about regulatory response to mouse hepatoma induction on page 31, the conditions set forth under points a-d (page 32), would be sufficient to trigger an extreme conservative regulatory stance even without mouse hepatoma induction.
The Committee has done an admirable job of laying out the various arguments, and they are to be strongly commended for their efforts. They have not resolved the arguments, but the report provides a basis for continuing debate and research to resolve the question of the relevance of chemically-induced mouse liver tumors to human risk. Until such time, it is felt that if a substance induces only mouse liver tumors, it should be considered safe until proven by more valid tests not to be so.
